ARCOMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.5 SEK | +2.66% |
|
+16.38% | +69.81% |
| 04-25 | Arcoma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 01-29 | Arcoma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 183M 16.73M 22.85M | Sales 2025 * | 199M 18.19M 24.85M | Capitalization | 178M 16.27M 22.23M |
|---|---|---|---|---|---|
| Net income 2024 * | 14M 1.28M 1.75M | Net income 2025 * | 16M 1.46M 2M | EV / Sales 2024 * | 0.93 x |
| Net cash position 2024 * | 7M 640K 874K | Net cash position 2025 * | 19M 1.74M 2.37M | EV / Sales 2025 * | 0.8 x |
| P/E ratio 2024 * |
13.1
x | P/E ratio 2025 * |
11.2
x | Employees | 31 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.66% | ||
| 1 week | +16.38% | ||
| Current month | +13.45% | ||
| 1 month | +14.41% | ||
| 3 months | +66.67% | ||
| 6 months | +76.47% | ||
| Current year | +69.81% |
1 week
11.40
14.15
1 month
11.2514.15
Current year
7.6014.15
1 year
6.3014.15
3 years
6.3021.60
5 years
6.3026.30
10 years
3.5726.30
| Managers | Title | Age | Since |
|---|---|---|---|
Johan Dahlberg
DFI | Director of Finance/CFO | 40 | 21-12-31 |
| Chief Tech/Sci/R&D Officer | 53 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | - | |
| Director/Board Member | 53 | 10-02-28 | |
Lars Kvarnhem
CHM | Chairman | 52 | 16-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 13.5 | +2.66% | 103,388 |
| 24-04-25 | 13.15 | +12.88% | 363,784 |
| 24-04-24 | 11.65 | -2.10% | 49,419 |
| 24-04-23 | 11.9 | -0.83% | 10,220 |
| 24-04-22 | 12 | +3.45% | 28,564 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotes
Arcoma AB is a Sweden-based medical technology company. It develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The Company's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).
Calendar
2024-08-14
- Q2 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +69.81% | 16.24M | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +11.68% | 239M | |
| +1.67% | 183M | |
| -.--% | 168M |
- Stock Market
- Equities
- ARCOMA Stock
